Key Insights

Highlights

Success Rate

64% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

25.0%

4 terminated out of 16 trials

Success Rate

63.6%

-22.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed with results

Key Signals

3 with results64% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (6)
P 1 (5)
P 2 (2)

Trial Status

Completed7
Terminated4
Recruiting4
Withdrawn1

Trial Success Rate

63.6%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT05293197Phase 1RecruitingPrimary

Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients

NCT05976490Not ApplicableRecruitingPrimary

NeuroPathways Intervention for Brain Tumor Patients

NCT06098248Not ApplicableTerminated

Evaluation of cCeLL-Ex Vivo Confocal Microscopy for Real-time Brain Tumor Diagnosis

NCT05669326Not ApplicableWithdrawnPrimary

Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery

NCT06092125Recruiting

Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease

NCT06099743Not ApplicableRecruitingPrimary

ASCENT Intervention for Brain Tumor Patients

NCT05169944Phase 1Completed

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

NCT04109209Not ApplicableCompleted

Psychological Intervention For Brain Tumor Caregivers

NCT02052648Phase 1Completed

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

NCT02880111TerminatedPrimary

Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa

NCT02885324Phase 2Terminated

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

NCT04351035Completed

National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry

NCT02798406Phase 2Completed

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

NCT02502708Phase 1Completed

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

NCT02128373Not ApplicableTerminated

A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer

NCT00418327Phase 1CompletedPrimary

Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Showing all 16 trials

Research Network

Activity Timeline